drugset / Trial / NCT00715039

Clinical Study Assessing a New Scale to Measure Onset of Action in Generalized Anxiety Disorder

NCT00715039

Completed 169 enrolled Pfizer
RandomizedParallel-groupTriple-blindBasic science

Summary

The study is to assess the performance characteristics of a new measure to assess onset of efficacy in a GAD patient population.

Timeline

Start
2003-10
Primary completion
Completion
2004-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lorazepam Small molecule 1.5 mg Oral
Comparator Paroxetine Small molecule 20 mg Oral

Indications